Characterization of CVID patients and healthy donors
| Group . | No. of patients . | Age, y . | Age at onset, y . | Sex M/F . | % peripheral B cells . | IgM in vitro, ng/mL . | IgG in vitro, ng/mL . |
|---|---|---|---|---|---|---|---|
| A | 6 | 39.7 ± 18.9 | 35.0 ± 20.7 | 4:2 | 6.1 ± 3.8 | 110 ± 130 | 0 |
| B | 19 | 42.7 ± 16.2 | 32.4 ± 12.9 | 11:8 | 7.8 ± 4.6 | > 4000* | 160 ± 200 |
| C | 5 | 44.4 ± 8.7 | 34.5 ± 8.6 | 2:3 | 10.8 ± 3.9 | > 7500 | > 1500 |
| Low B cells | 6 | 39.7 ± 8.5 | 28.1 ± 5.1 | 5:1 | 0.4 ± 0.4 | 20 ± 25 | 35 ± 42 |
| Sarcoidlike | 2 | 28 ± 4 | 24 ± 4 | 2:0 | 12.5 ± 10.5 | > 7500 | 190 ± 100 |
| HD | 22 | 32.4 ± 7.6 | NA | 12:10 | 7.7 ± 2.7 | > 7500 | > 1200† |
| Group . | No. of patients . | Age, y . | Age at onset, y . | Sex M/F . | % peripheral B cells . | IgM in vitro, ng/mL . | IgG in vitro, ng/mL . |
|---|---|---|---|---|---|---|---|
| A | 6 | 39.7 ± 18.9 | 35.0 ± 20.7 | 4:2 | 6.1 ± 3.8 | 110 ± 130 | 0 |
| B | 19 | 42.7 ± 16.2 | 32.4 ± 12.9 | 11:8 | 7.8 ± 4.6 | > 4000* | 160 ± 200 |
| C | 5 | 44.4 ± 8.7 | 34.5 ± 8.6 | 2:3 | 10.8 ± 3.9 | > 7500 | > 1500 |
| Low B cells | 6 | 39.7 ± 8.5 | 28.1 ± 5.1 | 5:1 | 0.4 ± 0.4 | 20 ± 25 | 35 ± 42 |
| Sarcoidlike | 2 | 28 ± 4 | 24 ± 4 | 2:0 | 12.5 ± 10.5 | > 7500 | 190 ± 100 |
| HD | 22 | 32.4 ± 7.6 | NA | 12:10 | 7.7 ± 2.7 | > 7500 | > 1200† |
Patients are characterized according to Bryant et al9 into subgroups A, B, and C and are compared with healthy donors (HD). Age, onset of disease, sex, percentage of peripheral B-cell count (as percentage of PBLs), and IgM and IgG in vitro production after SAC plus IL-2 stimulation are given. There was no statistically significant difference in age, age of onset, sex distribution, and percentage of peripheral B cells between the different subgroups of CVID patients.
CVID patients with low B-cell counts (< 1%) and sarcoidlike lesions were not included in further studies.
NA indicates not applicable.
Twelve of 19 produced more than 7500 ng/mL IgM.
Most healthy donors produced more than 1500 ng/mL IgG.